Literature DB >> 26521298

Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial".

Theodoros P Vassilakopoulos1, John Apostolidis2, Maria K Angelopoulou3.   

Abstract

Entities:  

Keywords:  aggressive B-cell lymphoma; first remission; randomized trial; rituximab maintenance

Mesh：

Substances：

Year:  2015        PMID： 26521298      PMCID： PMC4825295          DOI： 10.3324/haematol.2015.133223

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.

Authors:  Ekaterina Chigrinova; Michael Mian; Marta Scandurra; Timothy C Greiner; Wing C Chan; Julie M Vose; Giorgio Inghirami; Annalisa Chiappella; Luca Baldini; Maurilio Ponzoni; Andrés J M Ferreri; Silvia Franceschetti; Gianluca Gaidano; Alessandra Tucci; Fabio Facchetti; Thierry Lazure; Olivier Lambotte; Santiago Montes-Moreno; Miguel A Piris; Josep Fr Nomdedeu; Silvia Uccella; Paola M V Rancoita; Ivo Kwee; Emanuele Zucca; Francesco Bertoni
Journal:  Hematol Oncol       Date:  2011-03       Impact factor: 5.271

2.  Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab refractory patients.

Authors:  Michal Sieniawski; Shilpa Bhartia; Jennifer Wilkinson; Stephen John Proctor
Journal:  Leuk Lymphoma       Date:  2009-10

3.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Authors:  Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly
Journal:  Lancet       Date:  2010-12-20       Impact factor: 79.321

4.  The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

Authors:  Carsten Müller; Niels Murawski; Martin H J Wiesen; Gerhard Held; Viola Poeschel; Samira Zeynalova; Michael Wenger; Christina Nickenig; Norma Peter; Eva Lengfelder; Bernd Metzner; Tanja Rixecker; Carsten Zwick; Michael Pfreundschuh; Marcel Reiser
Journal:  Blood       Date:  2012-02-15       Impact factor: 22.113

5.  Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Laurie H Sehn; David W Scott; Mukesh Chhanabhai; Brian Berry; Anna Ruskova; Leanne Berkahn; Joseph M Connors; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

6.  Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.

Authors:  Gonzalo Gutiérrez-García; Lluis Colomo; Neus Villamor; Leonor Arenillas; Antonio Martínez; Teresa Cardesa; Adriana García-Herrera; Xavier Setoain; Sonia Rodríguez; Gabriela Ghita; Pau Abrisqueta; Eva Giné; Francesc Bosch; Elías Campo; Emilio Montserrat; Armando López-Guillermo
Journal:  Leuk Lymphoma       Date:  2010-07

7.  Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Authors:  Ulrich Jaeger; Marek Trneny; Helen Melzer; Michael Praxmarer; Weerasak Nawarawong; Dina Ben Yehuda; David Goldstein; Bilijana Mihaljevic; Osman Ilhan; Veronika Ballova; Michael Hedenus; Liang-Tsai Hsiao; Wing-Yan Au; Sonja Burgstaller; Gerhard Weidinger; Felix Keil; Christian Dittrich; Cathrin Skrabs; Anton Klingler; Andreas Chott; Michael A Fridrik; Richard Greil
Journal:  Haematologica       Date:  2015-04-24       Impact factor: 9.941

8.  Discordant bone marrow involvement in diffuse large B-cell lymphoma: comparative molecular analysis reveals a heterogeneous group of disorders.

Authors:  Marcus Kremer; Martin Spitzer; Sonja Mandl-Weber; Katrin Stecker; Burkhard Schmidt; Heinz Höfler; Leticia Quintanilla-Martínez; Falko Fend
Journal:  Lab Invest       Date:  2003-01       Impact factor: 5.662

9.  Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP.

Authors:  Hyoeun Shim; Jae-Il Oh; Sang Hyuk Park; Seongsoo Jang; Chan-Jeoung Park; Jooryung Huh; Cheolwon Suh; Hyun-Sook Chi
Journal:  J Clin Pathol       Date:  2013-05       Impact factor: 3.411
  9 in total
  3 in total

1.  Response to comment by P. Vassilakopoulos and colleagues.

Authors:  Ulrich Jaeger; Michael Praxmarer; Richard Greil
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

Review 2.  Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab.

Authors:  Sotirios G Papageorgiou; Thomas P Thomopoulos; Athanasios Liaskas; Theodoros P Vassilakopoulos
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

3.  Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.

Authors:  Xuan Zhou; Tingting Ma; Yichan Zhang; Na Zhou; Juan Li
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.